<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106340</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2308</org_study_id>
    <nct_id>NCT00106340</nct_id>
  </id_info>
  <brief_title>Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
      single oral drug. The purpose of this study is to assess the long term safety and
      effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in
      lowering overall blood glucose levels when added to metformin in people with type 2 diabetes
      not at target blood glucose levels on metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to HbA1c &gt;8%</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c at 5 years</measure>
    <time_frame>2 years (amended)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile after 5 years of treatment</measure>
    <time_frame>2 years (amended)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of failure for HbA1c from week 24 to 5 years</measure>
    <time_frame>2 years (amended)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose at 5 years</measure>
    <time_frame>2 years (amended)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight at 5 years</measure>
    <time_frame>2 years (amended)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3118</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>LAF237, Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin matching placebo</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride matching placebo</intervention_name>
    <arm_group_label>Vildagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On a stable dose of metformin as defined by the protocol

          -  Body mass index (BMI) in the range 22-45

          -  Blood glucose criteria must be met

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Type 1 diabetes

          -  Evidence of significant diabetic complications

          -  Evidence of serious cardiovascular complications

          -  Laboratory value abnormalities as defined by the protocol

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Centers</name>
      <address>
        <city>Nurnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2005</study_first_submitted>
  <study_first_submitted_qc>March 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2005</study_first_posted>
  <disposition_first_submitted>October 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 29, 2012</disposition_first_posted>
  <last_update_submitted>December 28, 2012</last_update_submitted>
  <last_update_submitted_qc>December 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals Corporation</organization>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

